Stealth BioTherapeutics Corp (MITO)

NASDAQ
1.5200
+0.0600(+4.11%)
Pre Market
1.5199
-0.0001(-0.01%)
- Real-time Data
  • Volume:
    901,205
  • Bid/Ask:
    1.4800/1.5000
  • Day's Range:
    1.4200 - 1.5800

MITO Overview

Prev. Close
1.52
Day's Range
1.42-1.58
Revenue
-
Open
1.44
52 wk Range
1.06-2.57
EPS
-0.98
Volume
901,205
Market Cap
965.34M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
5,234,486
P/E Ratio
-
Beta
-
1-Year Change
-20.83%
Shares Outstanding
635,092,150
Next Earnings Date
Aug 18, 2021
What is your sentiment on Stealth BioTherapeutics Corp?
or
Market is currently closed. Voting is open during market hours.

Stealth BioTherapeutics Corp News

Stealth BioTherapeutics Corp Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuyBuySell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyStrong BuyNeutralStrong Sell

Stealth BioTherapeutics Corp Company Profile

Stealth BioTherapeutics Corp Company Profile

Employees
29

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich’s ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber’s hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company’s product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson’s, Alzheimer’s, Huntington’s, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.

Read More
  • I'm holding this till atleast $7..could be years who knows maybe never
    0
    • not performing well at all, today. double digit drop from opening, why?
      0
      • The pattern that rises only before the stock market opens and always falls during regular time, is so predictable.
        1
        • pop up
          0
          • what's going on? why all of a sudden its going up after hrs??? wow
            0
            • good earnings? it's going up alot premarket
              0
              • HEDGIES MANIPULATION, ZERO SHORT SHARES FOR BORROW, THEY DO SAME TRICK WITH ALL STOCKS WITH HIGH UPWARDS, THEY THROW BIG AMOUNT OF SHARES TO MAKE FAKE EFFECT OF PUMP And DUMP AND IN THAR WAY THEY WANT TO MAKE PANIC SELL AND MANY STOP LOSS HAD BEEN TRIGGERED ON THE WAY DOWN, THEY DO WITH ALL STOCKS, JUST CHECK FEW EXAMPLES FROM Before few days $PRPO and $COCP or today SSY and NMRD, now you can get answer on GME revolution
                0
                • why is it falling??
                  0
                  • Why is it up so much?
                    0
                    • great news came out
                      0
                  • something is a brewin
                    0
                    • lol nope
                      0
                      • You think bro? support at 2.70 and an rsi crossover, but major downtrend
                        0
                        • You think bro? Some support off of 2.70 but major downtrend...
                          0
                          • hoping this bounces up after tge huge decline.
                            0
                            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.